Join the Wegovy group to help and get support from people like you.
Wegovy News
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 – For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes,...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 – Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease, according to a study...
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...
Use of GLP-1 Meds Have Risen 7-Fold Among Young Americans
WEDNESDAY, May 22, 2024 – The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 – For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research letter published...
'Hungry Gut' Gene Test Shows Who'll Benefit Most From Wegovy
TUESDAY, May 21, 2024 – You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only...
Semaglutide Has Lasting Benefit for Weight Loss
TUESDAY, May 21, 2024 – Semaglutide has a long-term beneficial impact on weight, as well as cardiovascular benefits, regardless of weight loss, according to two studies presented at the annual...
Stomach Paralysis Risk May Rise in People Taking Ozempic and Similar Drugs
MONDAY, May 20, 2024 – New, real-world research confirms that the blockbuster weight-loss drugs that millions of Americans have been taking to shed pounds can trigger stomach paralysis in some...
Semaglutide Reduces Need for Diuretics in Heart Failure
THURSDAY, May 16, 2024 – Semaglutide reduces the need for loop diuretics and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved...
Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
TUESDAY, May 14, 2024 – One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to...
GLP-1 Receptor Agonist Use Increases Likelihood of Antidepressant Prescription
WEDNESDAY, May 15, 2024 – Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants, according to a study published...
More Studies Support Wegovy's Long-Term Weight-Loss Benefits
TUESDAY, May 14, 2024 – Semaglutide – the active ingredient in the blockbuster weight-loss drugs Ozempic and Wegovy – can produce long-term weight and heart health benefits, a pair of new studies...
Wegovy Can Help Heart Failure Patients Reduce Meds: Study
MONDAY, May 13, 2024 – People with heart failure are often prescribed what are known as loop diuretic medications to help reduce the fluid buildup that's a hallmark of the disease. Now, research...
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 – For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online...
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction